MY171483A - Process for making isoquinoline compounds - Google Patents

Process for making isoquinoline compounds

Info

Publication number
MY171483A
MY171483A MYPI2015000128A MYPI2015000128A MY171483A MY 171483 A MY171483 A MY 171483A MY PI2015000128 A MYPI2015000128 A MY PI2015000128A MY PI2015000128 A MYPI2015000128 A MY PI2015000128A MY 171483 A MY171483 A MY 171483A
Authority
MY
Malaysia
Prior art keywords
compounds
isoquinoline compounds
making
making isoquinoline
hif
Prior art date
Application number
MYPI2015000128A
Other languages
English (en)
Inventor
Michael D Thompson
Jung Min Park
Michael P Arend
Original Assignee
Fibrogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48857024&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY171483(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fibrogen Inc filed Critical Fibrogen Inc
Publication of MY171483A publication Critical patent/MY171483A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MYPI2015000128A 2012-07-16 2013-07-15 Process for making isoquinoline compounds MY171483A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261672191P 2012-07-16 2012-07-16

Publications (1)

Publication Number Publication Date
MY171483A true MY171483A (en) 2019-10-15

Family

ID=48857024

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2015000128A MY171483A (en) 2012-07-16 2013-07-15 Process for making isoquinoline compounds

Country Status (22)

Country Link
US (2) US9340511B2 (enExample)
EP (2) EP2872487B1 (enExample)
JP (1) JP6196671B2 (enExample)
KR (1) KR102145272B1 (enExample)
CN (2) CN103435546B (enExample)
AU (1) AU2013290437B2 (enExample)
BR (1) BR112015001106B1 (enExample)
CA (1) CA2879238C (enExample)
CY (1) CY2022018I1 (enExample)
DK (1) DK2872487T3 (enExample)
ES (1) ES2631655T3 (enExample)
HU (2) HUE034409T2 (enExample)
IL (1) IL236625B (enExample)
IN (1) IN2015KN00265A (enExample)
MX (1) MX350922B (enExample)
MY (1) MY171483A (enExample)
NZ (1) NZ704660A (enExample)
PL (1) PL2872487T3 (enExample)
PT (1) PT2872487T (enExample)
SG (1) SG11201500234YA (enExample)
WO (1) WO2014014834A1 (enExample)
ZA (1) ZA201500664B (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102718708A (zh) 2003-06-06 2012-10-10 菲布罗根有限公司 含氮杂芳基化合物及其在增加内源性促红细胞生成素中的用途
JP5649584B2 (ja) 2008-11-14 2015-01-07 フィブロジェン インコーポレイテッド Ｈｉｆヒドロキシラーゼ阻害剤としてのチオクロメン誘導体
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
BR112015001106B1 (pt) 2012-07-16 2021-11-09 Fibrogen, Inc Métodos para a produção de compostos de isoquinolina
CN107540607A (zh) * 2012-07-16 2018-01-05 菲布罗根有限公司 脯氨酰羟化酶抑制剂的晶体形态
PT3003284T (pt) 2013-06-06 2020-08-10 Fibrogen Inc Formulações farmacêuticas de um inibidor da hidroxilase do fih
CN103694172A (zh) * 2013-12-26 2014-04-02 辽宁亿灵科创生物医药科技有限公司 含氮杂芳基化合物的衍生物
CN105384687B (zh) 2014-09-02 2018-05-01 广东东阳光药业有限公司 喹啉酮类化合物及其在药物中应用
WO2016045125A1 (en) * 2014-09-28 2016-03-31 Merck Sharp & Dohme Corp. Inhibitors of hif prolyl hydroxylase
CN104447547B (zh) * 2014-11-10 2017-04-19 苏州康润医药有限公司 4‑氨基异喹啉‑8‑甲酸甲酯的合成方法
CN106146490B (zh) * 2015-03-27 2018-10-23 沈阳三生制药有限责任公司 被芳氧基或杂芳氧基取代的5-羟基-1,7-萘啶化合物、其制备方法及其制药用途
CN104892509B (zh) * 2015-06-04 2018-03-09 苏州明锐医药科技有限公司 诺得司他的制备方法
CN106187888A (zh) * 2016-07-18 2016-12-07 江苏德源药业股份有限公司 Fg‑4592单晶及其制备方法
CN106478503A (zh) * 2016-09-29 2017-03-08 上海勋和医药科技有限公司 Roxadustat中间体的制备方法
CZ2016627A3 (cs) 2016-10-07 2018-04-18 Zentiva, K.S. Způsob přípravy (7-fenoxy-4-hydroxy-1-methylisochinolin-3-karbonyl)glycinu (roxadustatu) a jeho intermediátů založený na souběžném otevírání oxazolového kruhu, štěpení etheru a tvorbě iminu
CN107954931B (zh) * 2016-10-17 2021-06-22 上海医药集团青岛国风药业股份有限公司 一种诺得司他的制备方法
EP3573615B1 (en) * 2017-01-28 2024-06-12 Kingchem Life Science LLC A process for preparing 5-phenoxy-1(3h)isobenzofuranone
US20200299242A1 (en) * 2017-12-01 2020-09-24 Dr. Reddy's Laboratories Limited Process for the preparation of roxadustat and its intermediates
CN109956870A (zh) * 2017-12-14 2019-07-02 南京卡文迪许生物工程技术有限公司 一种罗沙司他的合成方法及其中间体化合物
CN110218184B (zh) * 2018-03-01 2022-09-27 广东东阳光药业有限公司 诺德司他共晶及其制备方法
CN110272386B (zh) * 2018-03-16 2022-09-09 上海医药集团青岛国风药业股份有限公司 一种诺得司他的制备方法
CN110526813B (zh) * 2018-05-24 2022-06-28 杭州科巢生物科技有限公司 异喹啉化合物的制备方法及其中间体
CN111978226B (zh) 2018-06-05 2022-03-04 沈阳化工大学 一种三氟乙基硫醚（亚砜）取代苯类化合物及其用途
CN113302175A (zh) 2018-11-09 2021-08-24 维瓦斯治疗公司 双环化合物
CN109776415B (zh) * 2019-03-07 2020-11-17 福建南方制药股份有限公司 一种Roxadustat中间体的制备方法
WO2020214734A1 (en) 2019-04-16 2020-10-22 Vivace Therapeutics, Inc. Bicyclic compounds
RU2709493C1 (ru) * 2019-08-01 2019-12-18 Марат Феликсович Фазылов Способ получения роксадустата
US20220340532A1 (en) * 2019-08-07 2022-10-27 Teva Pharmaceuticals International Gmbh Processes for the preparation of roxadustat and intermediates thereof
CN112441975B (zh) * 2019-09-03 2023-10-31 西藏嘉信景天药业有限公司 一种罗沙司他重要中间体的制备方法
US20230112619A1 (en) * 2019-10-18 2023-04-13 Shanghai Desano Chemical Pharmaceutical Co., Ltd. Method for preparing isoquinolinone compounds
CN112679431B (zh) * 2019-10-18 2023-05-05 上海迪赛诺化学制药有限公司 一种制备异喹啉酮类化合物的方法
CN112679430B (zh) * 2019-10-18 2023-05-05 上海迪赛诺化学制药有限公司 一种制备异喹啉酮类化合物的方法
CN113444042A (zh) * 2020-03-27 2021-09-28 南京海润医药有限公司 一种罗沙司他的制备方法
WO2021214785A1 (en) * 2020-04-21 2021-10-28 Mylan Laboratories Limited Improved process for the preparation of roxadustat
CN111533691A (zh) * 2020-06-08 2020-08-14 重庆三圣实业股份有限公司 一种罗沙司他的制备方法
CN113801060B (zh) 2020-06-13 2025-06-27 苏州鹏旭医药科技有限公司 一种多取代异喹啉化合物的制备方法
CN113816904B (zh) 2020-06-19 2022-08-12 济川(上海)医学科技有限公司 一种罗沙司他及其中间体的合成方法和其中间体
CN112409258B (zh) * 2020-11-20 2025-11-25 杭州科巢生物科技有限公司 一种罗沙司他的制备方法
CN114644589A (zh) * 2020-12-17 2022-06-21 鲁南制药集团股份有限公司 一种化合物n-[（4-羟基--1-甲基-3-异喹啉基）羰基]-甘氨酸的制备方法
CN114671807A (zh) * 2020-12-24 2022-06-28 联化科技（德州）有限公司 一种1-取代异喹啉类化合物的制备方法
US20230101768A1 (en) * 2021-08-13 2023-03-30 The Board Of Regents Of The University Of Texas System Method to treat manganese toxicity and manganese-induced parkinsonism in humans
CN116178260A (zh) * 2021-11-26 2023-05-30 四川国康药业有限公司 一种治疗肾性贫血的化合物及其制备方法
CN115124467A (zh) * 2022-07-11 2022-09-30 天津力生制药股份有限公司 一种罗沙司他关键中间体的制备方法
CN117105862B (zh) * 2023-07-26 2025-12-30 北京福元医药股份有限公司 一种罗沙司他及其中间体的制备方法
CN117486797A (zh) * 2023-11-23 2024-02-02 传健生物医药(厦门)有限公司 一种罗沙司他关键中间体及罗沙司他的制备方法

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4036964A (en) 1973-10-11 1977-07-19 Beecham Group Limited Isocarbostyril-3-carboxylic acid derivatives for the prophylaxis of asthma, hayfever and rhinitis
US3989704A (en) 1973-10-30 1976-11-02 Sandoz, Inc. 3-Substituted-4-aryl isoquinolines
DE2818423A1 (de) 1978-04-27 1979-11-08 Hoechst Ag Neue isochinolinderivate und verfahren zu ihrer herstellung
DE3233424A1 (de) 1982-09-09 1984-03-15 Hoechst Ag, 6230 Frankfurt Isochinolinderivate, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung
US4558006A (en) 1983-02-04 1985-12-10 Kirin-Amgen, Inc. A.T.C.C. HB8209 and its monoclonal antibody to erythropoietin
US4559403A (en) 1983-05-19 1985-12-17 Hoffmann-La Roche Inc. Substituted isoquinolines
US4584379A (en) 1985-01-22 1986-04-22 Merrell Dow Pharmaceuticals Inc. Isoquinoline thromboxane synthetase inhibitors
US4667016A (en) 1985-06-20 1987-05-19 Kirin-Amgen, Inc. Erythropoietin purification
US4822800A (en) 1986-06-09 1989-04-18 Ortho Pharmaceutical Corporation Isoquinolinol compounds having cardiotonic and phosphodiesterase fraction III inhibiting properties and/or renal vasodilating properties
US4966906A (en) 1987-11-27 1990-10-30 Hoechst-Roussel Pharmaceuticals Inc. 1-aryl-3-isoquinolinecarboxamides
US4952588A (en) 1987-11-27 1990-08-28 Hoechst-Roussel Pharmaceuticals Inc. 1-aryl-3-quinoline-and 1-aryl-3-isoquinoline-carboxamides
ES2101421T3 (es) 1993-11-02 1997-07-01 Hoechst Ag Amidas de acidos carboxilicos heterociclicos sustituidos, su preparacion y su utilizacion como medicamentos.
ES2101420T3 (es) 1993-11-02 1997-07-01 Hoechst Ag Esteres-amidas de acidos carboxilicos heterociclicos sustituidos, su preparacion y su utilizacion como medicamentos.
NZ270267A (en) 1993-12-30 1997-03-24 Hoechst Ag 3-hydroxypyridin-2yl (and -quinolin-2-yl) carboxamide derivatives and pharmaceutical compositions
WO1996018616A1 (en) 1994-12-12 1996-06-20 Merck & Co., Inc. Substituted 2-aminopyridines as inhibitors of nitric oxide synthase
IL135495A (en) 1995-09-28 2002-12-01 Hoechst Ag Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid
US6130231A (en) 1996-11-27 2000-10-10 Dupont Pharmaceuticals Integrin receptor antagonists
DE19746287A1 (de) 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
FR2779963A1 (fr) 1998-06-22 1999-12-24 Centre Nat Rech Scient Utilisation d'un compose possedant une affinite pour le recepteur mitochondrial des benzodiazepines en therapie du cancer
IT1302677B1 (it) 1998-10-15 2000-09-29 Zambon Spa Derivati benzazinici inibitori della fosfodiesterasi 4
AU4802500A (en) 1999-04-26 2000-11-10 Neurogen Corporation 2-aminoquinolinecarboxamides: neurokinin receptor ligands
IT1320162B1 (it) 2000-02-09 2003-11-18 Rotta Research Lab Derivati della tirosina ad attivita' anti leucotrienica, procedimentoper la loro preparazione e loro uso farmaceutico.
FI20002044A0 (fi) 2000-09-15 2000-09-15 Orion Yhtymae Oyj Comt-entsyymiä estäviä naftaleenijohdannaisia
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
US6855510B2 (en) 2001-03-20 2005-02-15 Dana Farber Cancer Institute, Inc. Pharmaceuticals and methods for treating hypoxia and screening methods therefor
JP4590157B2 (ja) 2001-03-21 2010-12-01 アイシス イノヴェイション リミテッド アッセイ、方法および手段
GB0107901D0 (en) * 2001-03-29 2001-05-23 Cyclacel Ltd Anti-cancer compounds
US6716866B2 (en) 2001-06-13 2004-04-06 Genesoft Pharmaceuticals, Inc. Aryl-benzimidazole compounds having antiinfective activity
WO2002100832A1 (en) 2001-06-13 2002-12-19 Genesoft Pharmaceuticals, Inc. Isoquinoline compounds having antiinfective activity
US6762318B2 (en) 2001-12-03 2004-07-13 Novo Nordisk A/S Glucagon antagonists
US8318703B2 (en) 2001-12-06 2012-11-27 Fibrogen, Inc. Methods for improving kidney function
EP1487472B1 (en) 2001-12-06 2019-06-26 Fibrogen, Inc. Treatment of ischemic or hypoxic conditions using heterocyclic carboxamides
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
US7618940B2 (en) 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
GB0229581D0 (en) * 2002-12-19 2003-01-22 Cyclacel Ltd Use
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
US20060251638A1 (en) 2003-06-06 2006-11-09 Volkmar Guenzler-Pukall Cytoprotection through the use of hif hydroxylase inhibitors
CN102718708A (zh) 2003-06-06 2012-10-10 菲布罗根有限公司 含氮杂芳基化合物及其在增加内源性促红细胞生成素中的用途
JP2007523870A (ja) 2003-07-15 2007-08-23 メルク　エンド　カムパニー　インコーポレーテッド ヒドロキシピリジンｃｇｒｐ受容体拮抗薬
EP1658074B1 (en) 2003-08-01 2012-11-07 Fibrogen, Inc. Inhibitors of 2-oxoglutarate dioxygenase as gamma globin inducers
US7208601B2 (en) 2003-08-08 2007-04-24 Mjalli Adnan M M Aryl and heteroaryl compounds, compositions, and methods of use
JP2007501844A (ja) 2003-08-08 2007-02-01 トランス　テック　ファーマ，インコーポレイテッド アリール及びヘテロアリール化合物、組成物並びに使用方法
ZA200610164B (en) 2004-05-28 2008-02-27 Fibrogen Inc HIF prolyl hydroxylase activity assay
AP2007004047A0 (en) * 2005-01-20 2007-06-30 Pfizer Ltd Substituted triazole derivatives as oxtocin antagonists
JP4792048B2 (ja) 2005-03-02 2011-10-12 ファイブロゲン インコーポレイティッド チエノピリジン化合物およびその使用方法
JP5390184B2 (ja) 2005-06-06 2014-01-15 ファイブローゲン、インコーポレーテッド 貧血の改良された治療方法
CN101242817B (zh) 2005-06-15 2016-08-31 菲布罗根公司 HIF1α调节剂在治疗癌症中的用途
US7831795B2 (en) * 2005-11-28 2010-11-09 Commvault Systems, Inc. Systems and methods for classifying and transferring information in a storage network
KR101446499B1 (ko) 2006-01-27 2014-10-06 피브로겐, 인크. 저산소증 유발가능 인자(ｈｉｆ)를 안정시키는 시아노이소퀴놀린 화합물
WO2007097929A1 (en) 2006-02-16 2007-08-30 Fibrogen, Inc. Compounds and methods for treatment of stroke
EP3124489B1 (en) 2006-04-04 2020-07-15 Fibrogen, Inc. Thiazolo-pyridine compounds as hif modulators
US7713986B2 (en) 2006-06-15 2010-05-11 Fibrogen, Inc. Compounds and methods for treatment of chemotherapy-induced anemia
US20070293575A1 (en) 2006-06-15 2007-12-20 Fibrogen, Inc. Compounds and methods for treatment of cancer-related anemia
EP2227475B1 (en) 2007-12-03 2014-02-19 Fibrogen, Inc. Isoxazolopyridine derivatives for use in the treatment of hif-mediated conditions
WO2009089547A1 (en) 2008-01-11 2009-07-16 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity
US8324405B2 (en) 2008-02-05 2012-12-04 Fibrogen, Inc. Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors
CN102264740B (zh) 2008-08-20 2014-10-15 菲布罗根有限公司 一种吡咯[1,2-b]哒嗪衍生物及其作为hif调节剂的用途
JP5649584B2 (ja) 2008-11-14 2015-01-07 フィブロジェン インコーポレイテッド Ｈｉｆヒドロキシラーゼ阻害剤としてのチオクロメン誘導体
WO2012097331A1 (en) 2011-01-13 2012-07-19 Fibrogen, Inc. Methods for increasing reticulocyte hemoglobin content
US8921389B2 (en) 2011-02-02 2014-12-30 Fibrogen, Inc. Naphthyridine derivatives as inhibitors of hypoxia inducible factor (HIF) hydroxylase
ES2606631T3 (es) * 2011-07-22 2017-03-24 Beijing Betta Pharmaceuticals Co., Ltd Formas polimeróficas de compuestos como inhibidor de la prolila hidroxilasa, y usos de los mismos
CA2866556C (en) 2012-03-09 2020-01-07 Fibrogen, Inc. 4 -hydroxy-isoquinoline compounds as hif hydroxylase inhibitors
BR112015001106B1 (pt) 2012-07-16 2021-11-09 Fibrogen, Inc Métodos para a produção de compostos de isoquinolina
CN107540607A (zh) 2012-07-16 2018-01-05 菲布罗根有限公司 脯氨酰羟化酶抑制剂的晶体形态
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
EP2951159B1 (en) 2013-01-24 2018-08-22 Fibrogen, Inc. Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid
PT3003284T (pt) 2013-06-06 2020-08-10 Fibrogen Inc Formulações farmacêuticas de um inibidor da hidroxilase do fih

Also Published As

Publication number Publication date
PL2872487T3 (pl) 2017-09-29
MX2015000505A (es) 2015-07-17
JP2015524409A (ja) 2015-08-24
EP3219706A1 (en) 2017-09-20
CN103435546A (zh) 2013-12-11
AU2013290437B2 (en) 2017-11-02
IL236625A0 (en) 2015-02-26
ES2631655T3 (es) 2017-09-01
US9708269B2 (en) 2017-07-18
CY2022018I2 (el) 2023-01-05
EP2872487A1 (en) 2015-05-20
HUE034409T2 (en) 2018-02-28
CA2879238C (en) 2021-08-10
KR102145272B1 (ko) 2020-08-18
CN103435546B (zh) 2016-08-10
US9340511B2 (en) 2016-05-17
US20150175550A1 (en) 2015-06-25
PT2872487T (pt) 2017-05-15
BR112015001106B1 (pt) 2021-11-09
AU2013290437A1 (en) 2015-02-19
CA2879238A1 (en) 2014-01-23
HUS2200030I1 (hu) 2022-07-28
IN2015KN00265A (enExample) 2015-06-12
US20160194285A1 (en) 2016-07-07
IL236625B (en) 2019-01-31
NZ704660A (en) 2017-10-27
WO2014014834A1 (en) 2014-01-23
ZA201500664B (en) 2017-08-30
SG11201500234YA (en) 2015-02-27
EP2872487B1 (en) 2017-04-26
JP6196671B2 (ja) 2017-09-13
CY2022018I1 (el) 2023-01-05
KR20150058147A (ko) 2015-05-28
CN106083719B (zh) 2019-10-18
CN106083719A (zh) 2016-11-09
BR112015001106A2 (pt) 2017-06-27
MX350922B (es) 2017-09-25
DK2872487T3 (en) 2017-06-06

Similar Documents

Publication Publication Date Title
MY171483A (en) Process for making isoquinoline compounds
MX2015006324A (es) Metodos para la fabricacion de polipeptidos proteoliticamente procesados.
NZ704662A (en) Crystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid
MX389228B (es) Composiciones para tratar el cabello.
MX360499B (es) Cepas microbianas, composiciones y metodos para incrementar el fosfato disponible para las plantas.
MY203474A (en) Substituted tricyclic compounds as fgfr inhibitors
IN2014DN08481A (enExample)
CA2902795C (en) Glycopyrrolate salts
MX347882B (es) Procedimiento mejorado para preparar (3e, 7e)-homofarnesol.
WO2014086982A3 (en) Stable metal compounds, their compositions and methods of their use
WO2014015210A3 (en) Microorganisms and processes for the conversion of glycerol to isoprene
AU2015287674B2 (en) Topical antiviral compositions and methods of using the same
MY195343A (en) A Novel Phtalazinone Derivatives and Manufacturing Process Thereof
MY197129A (en) Electrochemical coupling of two phenols which differ in their oxidation potential
WO2013168176A3 (en) Process for preparation of fosaprepitant and salt thereof
MX339772B (es) Metodo y composicion para producir azucar clarificada.
MX2015016603A (es) Composiciones de corticosteroides.
HK1212679A1 (zh) 他唑巴坦的制作工艺
MX2013005954A (es) Compuestos intermedios y procesos para la preparacion de derivados de quinolina tal como laquinimod sodico.
IN2014DN10135A (enExample)
IN2014DN07407A (enExample)
WO2014102759A3 (en) Process for the preparation of dasatinib and its intermediates
WO2014159501A3 (en) Processes for preparing tetrahydroisoquinolines
IN2015DN02513A (enExample)
PH12014502062A1 (en) Composition